What is Laronde?
Laronde is a pioneering company focused on programmable medicines, leveraging a unique bioplatform that integrates evolutionary principles with artificial intelligence. Their core technology combines eRNA and targeted nanoparticles (TNPs) to create a versatile toolkit for developing advanced RNA medicines. By employing sophisticated AI algorithms and rapid prototyping methodologies, Laronde aims to design and deploy novel RNA therapies targeting a broad spectrum of diseases, including autoimmune disorders, metabolic conditions, infectious diseases, and rare genetic ailments. The company is committed to driving transformative impacts through its cutting-edge technologies and data-centric strategies.
How much funding has Laronde raised?
Laronde has raised a total of $440M across 1 funding round:
Series B
$440M
Series B (2021): $440M with participation from Invus, T. Rowe Price Associates, and Flagship Pioneering
Key Investors in Laronde
Invus
Invus Group is an investment firm established in 1985, providing financial advice, investment services, and consulting. Headquartered in New York City, it specializes in strategic financial support for its portfolio companies.
T. Rowe Price Associates
T. Rowe Price Associates is a global investment management firm known for its research-driven approach to asset management, offering a wide range of investment solutions.
Flagship Pioneering
Flagship Pioneering, founded in 1999 and based in Cambridge, Massachusetts, is a venture capital firm dedicated to building transformative companies in human health and sustainability through deep scientific innovation.
What's next for Laronde?
The substantial enterprise-level funding Laronde has garnered, particularly the recent strategic investment, positions the company for significant scaling and further research and development. This capital is likely to accelerate the advancement of its programmable medicine platform and pipeline of therapeutic candidates. Laronde's focus on combining AI with biological innovation suggests a strategic push towards clinical validation and potential market entry for its novel RNA-based treatments, aiming to address unmet medical needs across various disease areas.
See full Laronde company page
